Literature DB >> 9330689

CD26/dipeptidyl peptidase IV in lymphocyte growth regulation.

S Ansorge1, F Bühling, T Kähne, U Lendeckel, D Reinhold, M Täger, S Wrenger.   

Abstract

DP IV/CD26 is involved in regulation of DNA synthesis and proliferation as well as production of cytokines of hematopoietic cells under various conditions. Inhibition of DNA synthesis in T lymphocytes, B lymphocytes, NK cells and myelomonocytic cells as well as of the production of IL-2, IL-6 TNF alpha, IL-1, IL-10, IL-12, IL-13, IFN-gamma, GM-CSF are not due to apoptosis of these cells. DP IV/CD26 inhibitors induce TGF-beta 1 mRNA synthesis and latent protein release demonstrating a crucial role of TGF-beta 1 in mediating CD26 function. X-X-Pro peptides as HIV-Tat protein strongly inhibit DP IV enzymatic activity and suppress DNA synthesis. This group of peptides may represent a class of natural DP IV/CD26 ligands and effectors, respectively. Hyperphosphorylation of p56lck as well as protein tyrosine phosphorylation of a number of proteins in T lymphocytes can be modulated by DP IV inhibitors. These data suggest that enzymatic activity or, at least in part, the active site of DP IV are both essential for its regulatory function in lymphocytes. Further work is required to determine the natural ligands, i.e. substrates and effectors, which are play the central role in DP IV/CD26 action in T cell growth and to understand the molecular mechanism of the early steps of this fundamental process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330689     DOI: 10.1007/978-1-4757-9613-1_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics.

Authors:  J Lin; P J Toscano; J T Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

2.  Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis.

Authors:  Y N Williams; H Baba; S Hayashi; H Ikai; T Sugita; S Tanaka; N Miyasaka; T Kubota
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.